A phase II study of pre-operative pegylated liposomal doxorubicin (PLD), paclitaxel, and trastuzumab in patients with operable breast cancer over-expressing Her2-Neu [human epidermal growth factor receptor 2]
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Jan 2010
At a glance
- Drugs Doxorubicin liposomal; Paclitaxel; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- 01 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 Sep 2007 QA'ed
- 29 Aug 2007 New trial record.